Clinical trials: Psoriasis Patients
Tuberculosis, Psoriasis
Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis
The purpose of this study is to determine the level of agreement between QuantiFeron -TB Gold test (QFT-G)and Tubeculin skin test (TST)for screening of latent tuberculosis in patients suffering from psoriasis.
- Trial name
- NCT01223976
- Testing
- Tuberculin skin test and Quantiferon -TB Gold test
- Where
- Israel
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Psoriatic Arthritis, Hand Rheumatism
Hand Exercises in Psoriatic Arthritis
This study is a randomized controlled study examining the effects of 8-week hand home exercises on grip strength, functionality, disease activity and quality of life in patients with PsA.
- Trial name
- NCT06263634
- Testing
- Hand exercises
- Where
- Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Akdeniz University
Psoriasis
Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet
Psoriasis is a chronic inflammatory disease that affects the skin and joints in 2-3 % of people in the United States. This inflammation of the skin, joints, and blood vessels in patients with psoriasis has been measured by older…
- Trial name
- NCT06574178
- Testing
- Dietary Counseling
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, Davis
Psoriasi
Effect of Adalimumab Therapy on Psoriasis Patient
to evaluate the impact of adalimumab therapy on quality of life in patient with severe psoriasis.
- Trial name
- NCT05889338
- Testing
- adalimumab and methotrexate
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Sohag University
Psoriasis
Vtama in Psoriasis Patients Being Treated With Biologics.
Open label study to assess 12 weeks of add-on VTAMA® (tapinarof) Cream, 1% QD in patients with ≥3% BSA who have received biologic therapy for at least 24 weeks.
- Trial name
- NCT06103695
- Testing
- Tapinarof
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Psoriasis
Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test
Clinical investigation of anti-psoriatic efficacy and atrophy
- Trial name
- NCT02111499
- Testing
- LAS41004-IMP1, LAS41004 IMP2, LAS41004 IMP3
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Almirall, S.A.
Rheumatoid Arthritis, Ankylosing Spondylitis
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
The aim of this post-marketing observational study is to obtain further data on the evaluation of quality of life outcomes of HUMIRA® in routine clinical use in patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT01083693
- Where
- 20 sites in Austria
- Volunteers
- 162 people
- Sponsor
- Abbott
Psoriatic Arthritis
A Study of Picankibart in Patients With Active Psoriatic Arthritis
This is a multicenter, randomized, double-blind, placebo-controlled Phase II/III clinical trial evaluating the efficacy and safety of picankibart (IBI112) in patients with active psoriatic arthritis (PsA).
- Trial name
- NCT07295509
- Testing
- Picankibart
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Arthritis, Psoriatic, Psoriasis
Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists
The purpose of this study is to evaluate the safety profile and the effectiveness of etanercept under usual care settings in patients with PsA treated by dermatologists.
- Conditions
- Arthritis, Psoriatic, Psoriasis, Skin Diseases, Papulosquamous
- Trial name
- NCT00293709
- Testing
- etanercept
- Where
- Germany
- Volunteers
- 129 people
- Sponsor
- Pfizer
Rheumatoid Arthritis, Psoriatic Arthritis
Surveillance of Humira Injection in Korean Patients
Patients who take Humira as prescribed by physicians as per Korean label will be enrolled and observed in normal medical practice setting for not less than 3 months following first dose of Humira.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease
- Trial name
- NCT01083121
- Where
- 77 sites in South Korea
- Volunteers
- 1,779 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)
PREVENER is a randomized, open-label, multicenter, phase IV clinical trial designed to evaluate the efficacy and safety of a carotid ultrasound-based strategy for the primary prevention of cardiovascular events in patients with…
- Conditions
- Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Axial Spondy, Systemic Lupus Erythematosus (SLE)
- Trial name
- PREVENER (NCT07611747)
- Testing
- Carotid Ultrasound, High-intensity lipid-lowering therapy, Standard care according to ESC 2021 guidelines
- Where
- 17 sites in Spain
- Volunteers
- 1,944 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Rheumatoid Arthritis, Psoriatic Arthritis
Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA.
This study will establish a comparison in follow-up care of 100 patients between Health Care Practitioners, more specifically the rheumatologist and a trained nurse.
- Trial name
- APRAN (NCT02556034)
- Testing
- Disease evaluation.
- Where
- Canada
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Isabelle Fortin
Chronic Plaque Psoriasis
Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis
This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to investigate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of Bimekizumab compared with…
- Trial name
- BE ABLE 1 (NCT02905006)
- Testing
- Bimekizumab
- Where
- 41 sites in United States, Canada and 4 more
- Volunteers
- 250 people
- Sponsor
- UCB Biopharma S.P.R.L.
Psoriatic Arthritis
A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab
The primary purpose of this study is to describe the Psoriatic Arthritis (PsA) participant profiles depending on whether their disease is managed by a dermatologist or by a rheumatologist in routine practice.
- Trial name
- PROUST (NCT03336281)
- Testing
- Ustekinumab
- Where
- France
- Volunteers
- 221 people
- Sponsor
- Janssen Cilag S.A.S.
Psoriasis
Excimer Laser, Serum Markers & Psoriasis
The overall aims for this study are to determine whether UVB excimer laser treatment of psoriasis affects serum inflammatory markers, and to assess hyperpigmentation and erythema with excimer laser treatment.
- Trial name
- NCT02165657
- Testing
- Excimer laser treatment
- Where
- United States
- Sponsor
- University Hospitals Cleveland Medical Center
Arthritis; Psoriasis (Etiology)
Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic Arthritis
This study aims to evaluate more objectively, through an imaging technique such as ultrasound, changes in joints and entheses of patients with active psoriatic arthritis (PAs) who will start treatment with Apremilast after the…
- Trial name
- APREMILAST (NCT03191539)
- Testing
- Apremilast
- Volunteers
- 56 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Moderate-to-severe Chronic Plaque Psoriasis
Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)
The purpose of this study is to evaluate the effectiveness and safety of adalimumab as used in routine clinical practice in adult patients with moderate to severe chronic plaque psoriasis in Spain.
- Trial name
- PROMISE (NCT01076192)
- Volunteers
- 547 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriatic Arthritis
Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient
Psoriasis is a chronic, immune-mediated, multisystemic, inflammatory disease caused by the interaction of multiple susceptibility genes and environmental factors that affects 1-3% of the population worldwide .Psoriasis also is a…
- Trial name
- NCT06870500
- Testing
- Methotrexate
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- South Valley University
Chronic Plaque Psoriasis
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis
This is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in adult subjects with moderate to severe chronic…
- Trial name
- NCT03025542
- Testing
- Bimekizumab
- Where
- 8 sites in United States, Australia and 2 more
- Volunteers
- 49 people
- Sponsor
- UCB Biopharma SRL
Plaque Psoriasis
Cell Responses to IFN-gamma
IFN-gamma is a central player in the development of psoriasis lesions, which can be involved a variety of cellular processes in the skin.
- Trial name
- NCT01317017
- Testing
- Actimmune
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.